1-5 of 5
Marketa Zackova
Close
Sort by
Journal Articles

ASP210 - a Potent Oligonucleotide-Based Inhibitor for Combating Both BCR-ABL1 Dependent and Independent TKI-Resistant CML Cells

Veronika Nemethova, Petra Mazancova, Boglarka Nemethova, Lucia Uhelska, Andrea Babelova, Michal Selc, Kristina Jakic, Ondrej Mitrovsky, Denisa Myslivcova, Marketa Zackova, Alexandra Poturnayova, Angelika Batorova, Antonia Hatalova, Katarina Slezakova, Lubos Drgona, Iveta Oravcova, Eva Mikuskova, Ludmila Demitrovicova, Andrej Vranovsky, Filip Razga
Journal: Blood
Blood (2022) 140 (Supplement 1): 12995–12996.
https://doi.org/10.1182/blood-2022-166148
Published: 2022
Journal Articles

The Musashi 2 mRNA Expression in the Course of CML.

Sylvie Nadvornikova, Marketa Zackova, Tereza Lopotova, Hana Klamova, Jana Moravcova
Journal: Blood
Blood (2012) 120 (21): 2552.
https://doi.org/10.1182/blood.V120.21.2552.2552
Published: 2012
Journal Articles

HSP90 Chaperone – An Important Player in CML: Study At RNA and Protein Level

Marketa Zackova, Tereza Lopotova, Sylvie Nadvornikova, Hana Klamova, Jana Moravcova
Journal: Blood
Blood (2011) 118 (21): 4878.
https://doi.org/10.1182/blood.V118.21.4878.4878
Published: 2011
Journal Articles

Supportive Methods for Testing CML Progression in Addition to BCR-ABL Transcript Monitoring – What to Do If BCR-ABL Monitoring doesn't Work?

Tereza Lopotova, Marketa Zackova, Sylvie Nadvornikova, Hana Klamova, Jana Moravcova
Journal: Blood
Blood (2011) 118 (21): 4902.
https://doi.org/10.1182/blood.V118.21.4902.4902
Published: 2011
Journal Articles

In Vitro Sensitivity to Tyrosine Kinase Inhibitors Is One of Possible Predictive Parameters for Therapy Switch In Patients with Chronic Myeloid Leukemia

Marketa Zackova, Tereza Lopotova, Zuzana Ondrackova, Hana Klamova, Jana Moravcova
Journal: Blood
Blood (2010) 116 (21): 2747.
https://doi.org/10.1182/blood.V116.21.2747.2747
Published: 2010